Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.33 |
| ▸ | QPCT | Q16769 | 5/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945614 | 0.82 | ADORA2B (0.42) | ADORA2BRXFP1 | |
| SCHEMBL14945705 | 0.77 | ADORA2B (0.56) | DUTADORA2BRXFP1 | |
| SCHEMBL2774758 | 0.77 | ALDH1A1 (0.46) | DUTQPCTADORA1 | |
| SCHEMBL14945618 | 0.77 | KMT2A (0.40) | DUTADORA2BRXFP1 | |
| SCHEMBL14945639 | 0.76 | KMT2A (0.40) | DUTADORA2BRXFP1 | |
| SCHEMBL14945670 | 0.73 | ELANE (0.35) | RXFP1 | |
| SCHEMBL14945675 | 0.67 | ADORA2B (0.47) | ADORA2B | |
| SCHEMBL14945492 | 0.67 | ALDH1A1 (0.31) | RXFP1 | |
| SCHEMBL20220634 | 0.67 | ADORA2B (0.43) | ADORA2B | |
| SCHEMBL18959798 | 0.67 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944655-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DUT 619/4885ADORA2B 3395/4885QPCT 134/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DUT 619/4885ADORA2B 3395/4885QPCT 134/4885 |
| US-20160297834-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | DUT 619/4885ADORA2B 3395/4885QPCT 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.